GreenLight Biosciences Holdings PBC (GRNA) Forecast, Price Target & Analyst Ratings

NASDAQ:GRNA • US39536G1058

Current stock price

0.2995 USD
0 (-0.03%)
At close:
0.2995 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for GreenLight Biosciences Holdings PBC (GRNA).

Forecast Snapshot

Consensus Price Target

Price Target
$0.46
+ 53.26% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Aug 14, 2023
Period
Q2 / 2023
EPS Estimate
-$0.27
Revenue Estimate
510K
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
45.71%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$0.46
Upside
+ 53.26%
From current price of $0.30 to mean target of $0.46, Based on 7 analyst forecasts
Low
$0.30
Median
$0.46
High
$0.63

Price Target Revisions

1 Month
0.00%
3 Months
-80.43%

Price Target Summary

7 Wall Street analysts provided a forecast for the next 12 months for GRNA. The average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.
The average price target has been revised downward by 80.43% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

GRNA Current Analyst RatingGRNA Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0 0 0 0 0

Analyst Ratings History

GRNA Historical Analyst RatingsGRNA Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -8 -7 -6 -5 -4 -3 -2 -1 0 2 4 6

Analyst Ratings Consensus

ChartMill Buy Consensus
45.71%
GRNA was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about GRNA.
In the previous month the buy percentage consensus was at a similar level.
GRNA was analyzed by 7 analysts. More opinions would make the average more meaningful.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2023-05-31Canaccord GenuityDowngrade Buy -> Hold
2022-12-08Canaccord GenuityInitiate Buy
2022-10-14Credit SuisseInitiate Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date
Aug 14, 2023
Period
Q2 / 2023
EPS Estimate
-$0.27
Revenue Estimate
510K
Revenue Q2Q
-71.15%
EPS Q2Q
N/A
Number of Analysts
4

Next Earnings Revisions

Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
-58.24%
EPS (3 Months)
-7.82%

Next Earnings Summary

GRNA is expected to report earnings on 8/14/2023. The consensus EPS estimate for the next earnings is -0.27 USD and the consensus revenue estimate is 510.00K USD.
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2023 - 2024

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2020 2021 2022 2023 2024
Revenue
YoY % growth
GRNA revenue by date.GRNA revenue by date.
1.747M
-41.79%		1.595M
-8.70%		6.78M
325.08%		7.242M
6.81%		17.969M
148.12%
EBITDA
YoY % growth
GRNA ebitda by date.GRNA ebitda by date.
N/A-102.786M-154.884M
-50.69%		-127.194M
17.88%		-126.174M
0.80%
EBIT
YoY % growth
GRNA ebit by date.GRNA ebit by date.
-52.284M
-79.04%		-108.558M
-107.63%		-162.96M
-50.11%		-136.374M
16.31%		-137.394M
-0.75%
Operating Margin
GRNA operating margin by date.GRNA operating margin by date.
-2,992.79%-6,806.14%-2,403.54%-1,883.10%-764.62%
EPS
YoY % growth
GRNA eps by date.GRNA eps by date.
N/AN/AN/A-0.85
26.28%		-0.83
1.74%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q2 / 23 Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-0.27-0.26
10.32%		-0.24
4.12%
Revenue
Q2Q % growth		510K
-71.15%		510K
-70.55%		2.244M
-25.77%
EBITDA
Q2Q % growth		-38.006M
20.56%		-37.781M
-24.44%		-38.108M
-27.42%
EBIT
Q2Q % growth		-30.906M
40.52%		-30.294M
16.40%		-29.478M
22.39%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

GRNA Yearly Revenue VS EstimatesGRNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 5M 10M 15M
GRNA Yearly EPS VS EstimatesGRNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 -0.2 -0.4 -0.6 -0.8 -1

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

GreenLight Biosciences Holdings PBC / GRNA Forecast FAQ

What is the average price target for GreenLight Biosciences Holdings PBC (GRNA) stock?

7 analysts have analysed GRNA and the average price target is 0.46 USD. This implies a price increase of 53.26% is expected in the next year compared to the current price of 0.2995.

What is the next earnings date for GRNA stock?

GreenLight Biosciences Holdings PBC (GRNA) will report earnings on 2023-08-14, after the market close.

Can you provide the consensus estimates for GreenLight Biosciences Holdings PBC next earnings?

The consensus EPS estimate for the next earnings of GreenLight Biosciences Holdings PBC (GRNA) is -0.27 USD and the consensus revenue estimate is 510.00K USD.

How many analysts have analysed GreenLight Biosciences Holdings PBC (GRNA)?

The number of analysts covering GreenLight Biosciences Holdings PBC (GRNA) is 7.